Y Mabs Therapeuticsincis A Biopharmaceutical Company Focused On Developing Innovative Cancer Treatmentsparticularly For Rare Pediatric Cancersfounded In April 2015 By Thomas Gadthe Company Aims To Address High Unmet Medical Needs In Oncologyy Mabs Leverages Advanced Technologies Licensed From Memorial Sloan Kettering Cancer Center To Create Targeted Therapies The Companyae S Key Offerings Include Danyelzaa Naxitamab Gqgk The First Fda Approved Therapy For Relapsed Or Refractory High Risk Neuroblastomay Mabs Also Utilizes Its Sada Prit Platform For Pretargeted Radioimmunotherapy And The Y Biclone Platform For Generating Bispecific Antibodiesthese Technologies Are Designed To Deliver Precise Treatments While Minimizing Side Effectsy Mabs Is Committed To Expanding Its Global Reach And Improving Access To Its Therapies For Patients With Aggressive Cancers
No conferences found for this company.
| Company Name | Y Mabs Therapeutics As |
| Country |
Denmark
|
| Address | N/A |
| Telephone | N/A |
| N/A |
